Article
Benefits of PDT more far-reaching than previously expected
Orlando-Photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis Ophthalmics) is used widely to treat predominantly classic choroidal neovascularization (CNV) in age-related macular degeneration (AMD). The therapy, however, has met clinician resistance for treating occult CNV despite good visual results in the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study and the Verteporfin in Photodynamic Therapy (VIP) Trial, according to Joan W. Miller, MD.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
